AntiTNF-α strategy: Present status of this therapeutic paradigm

Indian Journal of Pharmacology

Volumn 36, Issue 1, 2004, Pages 10-14

  Singh, J ^a   Suruchi, A ^a  

^a POST GRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

AntiTNF therapy; Etanercept; Infliximab; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; AMIODARONE; ANETHOLE TRITHIONE; CYCLOSPORIN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; GLUCOCORTICOID; GREPAFLOXACIN; INFLIXIMAB; INTERLEUKIN 8; ISOPRENALINE; METHOTREXATE; MILRINONE; MYCOPHENOLIC ACID; OLOPATADINE; ONERCEPT; OUABAIN; PENTOXIFYLLINE; PIPERANOMETOZINE; PYRROLIDINE DITHIOCARBAMATE; RESVERATROL; ROPIVACAINE; ROTENONE; TOREMIFENE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG;

ANEMIA; ANKYLOSING SPONDYLITIS; ARTICLE; ASTHMA; BLEEDING; CANCER; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CROHN DISEASE; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; HUMAN; HYPERSENSITIVITY REACTION; INJECTION PAIN; LYMPHOMA; NEUROPATHY; PANCYTOPENIA; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SEPSIS; SEPTIC SHOCK; STROKE; TUBERCULOSIS;

EID: 1142299513     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Huang Y, Krein PM, Muruve DA, Winston BW. Complement factor B gene regulation: Synergistic effects of tumor necrosis factor-alpha and interferon-gamma in macrophages. J Immunol 2002;169:2627-35.
2. Berleth ES, Nadadur S, Henn AD, Eppolito C, Shiojiri S, Gurtoo HL, et al. Identification, characterization and cloning of TIP-B1, a noval protein inhibitor of tumor necrosis factor induced lysis. Cancer Res 1999;59:5497-506.
3. Thomas PS. Tumor necrosis factor alpha: The role of this multiple cytokine in asthma. Immunol Coll Biol 2001;79:132-40.
4. Zaremba J. Contribution of tumor necrosis factor alpha to the pathogenesis of stroke. Folia Morphol 2000;59:137-43.
5. Keystone EC. Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:427-43.
6. van Balkon BP, Schoon EJ, Stockbrugger RW, Walters FL, van Hogezand RA, van Deventer SJ, Oldenburg B. Effect of anti TNF-α therapy on quality of life in Crohn's disease. Aliment Pharmacol Ther 2002;16:1101-7.
7. Lilli C, Marinucci L, Bellocchio S, Ribatti D, Balducci C, Baroni T, et al. Effects of TGF-β1 and TNF-alpha on cultured fibroblast from skin fibroma as modulated by toremifene. Int J Cancer 2002;98:824-32.
8. Appoloni O, Dupont E, Vandercruys M, Andriens M, Duchateau J, Vincent JL. Association of TNF-alpha allele with plasma TNF-alpha levels and mortality from septic shock. Am J Med 2001;110:486-8.
9. Kupfermine MJ, Peaceman AM, Wigton TR, Rehnberg KA, Socol ML. Tumor necrosis factor-alpha is elevated in plasma and amniotic fluid of patients with severe preeclampsia. Am J Obstet Gynecol 1994;170:1752-7.
10. Henriksen PA, Newby DE. Therapeutic inhibition of tumor necrosis factor-α in patients with heart failure: cooling an inflamed heart. Heart 2003;89:14-8.
11. Vincent JL. Afelimomab. Int J Clin Pract 2000;54:190-3.
12. Markhan A, Lamb HM. Infliximab: A review of its use in the management of rheumatoid arthritis. Drugs 2000;59:1341-59.
13. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human antiTNF-α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003;48:35-45.
14. Sandborn J. Strategies for targeting tumor necrosis factor in inflammatory bowel disease. Best Pract Clin Gastroenterol 2003;17:105-17.
15. Rechless J, Tatalick LM, Grainger DJ. The pan-chemokine inhibitor NR58-3.14.3 abolishes tumour necrosis factor-alpha accumulation and leucocyte recruitment induced by lipopolysaccharide in vivo. Immunology 2001;103: 244-54.
16. Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, Mc-Tiernan C. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000;35:537-44.
17. Davey PP, Ashrafian H. New therapies for heart failure: is thalidomide the answer? QJM 2000;93:305-11.
18. Hashimoto S, Matsumoto K, Gon Y, Maruoka S, Hayashi S, Asai Y, et al. Grepafloxacin inhibits tumor necrosis factor-alpha-induced IL-8 expression in human airway epithelial cells. Life Sci 2000;66:77-82.
19. Van Rijan MML, Metselaar HJ, Hommes M, Ijzermans JN, Tilanus HW, Kwekkeboam J. Mycophenolic acid is a potent inhibitor of the expression of tumor necrosis factor and tumor necrosis factor receptor superfamily costimulatory molecules. Immunology 2003;109:109-16.
20. Gahring LC, Carlson NG, Weiggel WA. Alcohol blocks TNF-alpha but not other cytokine-mediated neuroprotection to NMDA. Alcohol Clin Exp Res 1999;23:1571-9.
21. Zhang XW, Thorlacius H. Inhibitory actions of ropivacaine on TNF-alpha-induced leukocyte adhesion and tissue accumulation in vivo. Eur J Pharmacol 2000;392:1-3.
22. Salas A, Sans N, Soriano A, Reverter JC, Anderson DC, Pique JM, et al. Heparin attenuates TNF-alpha-induced inflammatory response through a CD-11b dependent mechanism. Gut 2000;47:88-96.
23. Chandel NS, Trzyna WC, McClintock DS, Schumacker PT. Role of oxidants in NF-KB activation and TNF-alpha gene transcription induced by hypoxia and endotoxin. J Immunol 2000;165:1013-21.
24. Manna SK, Mukhopadhyay A, Aggarwal BB. Resveratrol suppresses TNF-induced activation of nuclear transcription factor NF-KB, activator protein-1 and apoptosis: Potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 2000;164:6509-19.
25. Camussi G, Lupia E. The future role of antitumor necrosis factor products in the treatment of rheumatoid arthritis. Drugs 1998;55:613-20.
26. Smith MD. Etanercept treatment of rheumatoid arthritis in the "real world". Ann Rheum Dis 2003;62:95-6.
27. Feldmann M, Maini RN. Anti-TNF-alpha therapy of rheumatoid arthritis: What we have learnt? Ann Rev Immunol 2001;19:163-96.
28. Kavanaugh A, St Clair EW, Mc Cune WJ, Braakman T, Lipsky P. Chimeric antitumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2001;27: 841-50.
29. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of acute ankylosing spondylitis with antitumor necrosis factor-alpha monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.
30. Braun J, Sieper J, Breban M, Callanles Estevz E, Davis J, Inman R, et al. Antitumor necrosis factor-alpha therapy for ankylosing spondylitis: International experience. Ann Rheumatol Dis 2002;61:51-60.
31. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, Van-Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
32. Blam MF, Stein RB, Lichen Stein GR. Integrating antitumor necrosis factor therapy in inflammatory bowel disease. Current and future perspectives. Ann J Gastroenterol 2001; 96:1977-97.
33. Hotamisligil GS. The role of TNF-alpha and TNF-receptors in obesity and insulin resistance. J Intern Med 1999;245:621-5.
34. Lamhamedi-Cherradi SE, Zhengs S, Tisch RM, Chen YH. Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type I diabetes. Diabetes 2003;52:2274-8.
35. Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, et al. Safety and efficacy of soluble P75 TNF receptor (enbrel, etanercept) in patients with advanced heart failure. Circulation 1999; 99:3224-6.
36. Venters HD, Dantzer R, Kelley KW. Tumor necrosis factor-alpha-induce neuronal death by silencing survival signals generated by the type I insulin-like growth factor receptor. Ann NY Acad Sci 2000; 917:210-20.
37. Fekade D, Knox K, Hussein K, Melka A, Lalloo DG, Coxon RE, et al. Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor. N Engl J Med 1996;335:311-5.
38. Abraham E, Wunderink R, Silverman H, Pari TM, Nasraway S, Levy H, et al. Efficacy and safety of monoclonal antibody to tumor necrosis factor-alpha in patients with sepsis syndrome. A randomized, controlled, double blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. J Am Med Assoc 1995;273:334-41.
39. Mauceri HJ, Seetharam S, Beckett MA, Lee JY, Gupta VK, Gately S, et al. Tumor production of angiostatin is enhanced after exposure to TNF-alpha. Int J Cancer 2002;97:410-5.
40. Naylor MS, Stamp GW, Foulke WD, Eccles D, Balkwill FR. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 1993;91:2194-206.
41. Hajeer AH, Lear JT, Ollier WE, Naves M, Worthington J, Bell DA, et al. Preliminary evidence of association of TNF microsatellites with increased risk of multiple basal cell carcinomas. Br J Dermatol 2000;142:441-5.
42. Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H. Nature's TRAIL on a path to cancer immunotherapy. Immunity 2003;18:1-6.
43. Lin T, Zhang L, Davis J, Gu J, Nishizaki M, Ji L, et al. Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. Mol Ther 2003;8:441-8.
44. Chaudhari U, Romano P, Mulcahy LD, Dooley J, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomized trial. Lancet 2001;357:1842-7.
45. Camp RD. Updates from the IIIrd international congress on psoriasis. From gene to clinic. Br J Dermatol 2003;148:878-84.
46. Mimouni D, Anhalt GJ, Kauba DJ, Nousari HC. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol 2003;148:813-6.
47. Voigtlander C, Luftl M, Schuler G, Hertl M. Infliximab (anti TNF-α antibody): a novel highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Arch Dermatol 2001;137:1571-4.
48. Warnnissorn P, Nakao A, Suto H, Ushio H, Yamaguchi N, Yagita H, et al. Tumor necrosis factor related apoptosis-inducing ligand expression in atopic dermatitis. Br J Dermatol 2003;148:829-31.
49. Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, et al. Anti TNF-α monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003;38:419-25.
50. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature 1994;371:508-10.
51. Jeon EJ, Park YS, Choi YC, Yeo SW, Jung TT. Effect of inhibitor of TNF-α on experimental otitis media with effusion. Ann Otol Rhinol Laryngol 2001;110: 917-21.
52. Szold O, Ben Abraham R, Frolkis I, Sorkine M, Sorkine P. TNF as a mediator of cardiac toxicity following snake envenomation. Crit Care Med 2003;31:1449-53.
53. Labunski S, Posern G, Ludwig S, Kundt G, Brocker EB, Kunz M. Tumor necrosis factor-alpha promoter polymor-phism in erythema nodosum. Acta Derm Venereol 2001;81:18-21.
54. Reimold AM. New indications for treatment of chronic inflammation by TNF-alpha blockade. Am J Med Sci 2003; 325:75-92.
55. Hengstman GJ, van den Hoogen FH, Barrera P, Netea MG, Pieterse A, van de Putte LB, et al. Successful treatment of dermatomyositis and polymyositis with antitumor necrosis factor-alpha: Preliminary observations. Eur Neurol 2003;50:10-5.
56. Mc Cain ME, Quinet RJ, Davis WE. Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology 2002;41:116-7.